Published in J Virol on May 01, 2005
Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol (2007) 1.22
Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis (2008) 1.18
Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis (2006) 1.17
Evidence of recombination in intrapatient populations of hepatitis C virus. PLoS One (2008) 1.16
The quasispecies nature and biological implications of the hepatitis C virus. Infect Genet Evol (2009) 1.14
Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J Virol (2012) 1.10
Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5' untranslated regions. J Clin Microbiol (2006) 1.09
Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol (2009) 1.07
A new evolutionary model for hepatitis C virus chronic infection. PLoS Pathog (2012) 1.02
Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol J (2011) 0.97
HCV and lymphoproliferation. Clin Dev Immunol (2012) 0.96
Molecular evolution in court: analysis of a large hepatitis C virus outbreak from an evolving source. BMC Biol (2013) 0.95
Comparative analysis of hepatitis C virus phylogenies from coding and non-coding regions: the 5' untranslated region (UTR) fails to classify subtypes. Virol J (2006) 0.95
Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. World J Gastroenterol (2010) 0.95
Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection. J Infect Dis (2007) 0.95
Role of miR-122 and lipid metabolism in HCV infection. J Gastroenterol (2012) 0.89
Hepatitis C virus and peripheral blood mononuclear cell reservoirs Patricia Baré. World J Hepatol (2009) 0.86
Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients. Virus Res (2007) 0.85
Analysis of in vitro replicated human hepatitis C virus (HCV) for the determination of genotypes and quasispecies. Virol J (2006) 0.83
Unique and differential protein signatures within the mononuclear cells of HIV-1 and HCV mono-infected and co-infected patients. Clin Proteomics (2012) 0.83
Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation. Virology (2010) 0.82
Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PLoS One (2012) 0.81
Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle? Virology (Auckl) (2013) 0.79
Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses. Mol Ther (2013) 0.78
Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. World J Gastroenterol (2014) 0.78
Detection of Newcastle disease virus minor genetic variants by modified single-stranded conformational polymorphism analysis. Biomed Res Int (2014) 0.78
Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV. J Med Virol (2014) 0.78
Human Interferon Regulatory Factor 2 Gene Expression is Induced in Chronic Hepatitis C Virus Infection-A Possible Mode of Viral Persistence. J Clin Exp Hepatol (2012) 0.77
Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients. J Clin Microbiol (2014) 0.77
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin. Medicine (Baltimore) (2015) 0.77
Compartmentalization of hepatitis B virus: Looking beyond the liver. World J Hepatol (2015) 0.77
A New Twist to a Chronic HCV Infection: Occult Hepatitis C. Gastroenterol Res Pract (2015) 0.77
Analysis of a non-structural gene reveals evidence of possible hepatitis C virus (HCV) compartmentalization. J Med Virol (2012) 0.77
Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther (2016) 0.76
Analysis of the 5'UTR of HCV genotype 3 grown in vitro in human B cells, T cells, and macrophages. Virol J (2010) 0.76
Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection. PLoS Pathog (2016) 0.76
Is single-strand conformation polymorphism analysis of the full 5' untranslated region an adequate approach to study hepatitis C virus quasispecies distribution? J Virol (2009) 0.76
Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients. J Virol (2015) 0.76
Bioinformatic Analysis of Codon Usage and Phylogenetic Relationships in Different Genotypes of the Hepatitis C Virus. Hepat Mon (2016) 0.75
Advanced molecular surveillance of hepatitis C virus. Viruses (2015) 0.75
The hepatitis C virus 5'UTR genomic region remains highly conserved under HAART: a 4- to 8-year longitudinal study from HCV/HIV co-infected patients. AIDS Res Hum Retroviruses (2010) 0.75
Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A (1989) 18.26
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Protection against persistence of hepatitis C. Lancet (2002) 5.94
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
The epidemic behavior of the hepatitis C virus. Science (2001) 4.81
Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology (1999) 3.83
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol (1996) 3.22
Directed egress of animal viruses promotes cell-to-cell spread. J Virol (2002) 2.72
Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med (2002) 2.56
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 2.49
Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol (2004) 2.27
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol (2002) 2.05
In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood (1998) 1.98
Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest (1996) 1.79
Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology (1998) 1.74
Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis (2000) 1.66
Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. J Infect Dis (2001) 1.54
Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J Virol (1999) 1.42
Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. J Gen Virol (1998) 1.42
International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods (1996) 1.41
Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology (2004) 1.41
How viruses escape from cytotoxic T lymphocytes: molecular parameters and players. Virology (1997) 1.39
Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver. J Virol (2000) 1.23
The origin of hepatitis C virus reinfecting transplanted livers: serum-derived versus peripheral blood mononuclear cell-derived virus. J Infect Dis (2002) 1.19
Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology (1999) 1.19
Sequence analysis of the hepatitis C virus genome recovered from serum, liver, and peripheral blood mononuclear cells of infected chimpanzees. J Virol (1997) 1.17
Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. Transplantation (1998) 1.07
The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis (1998) 1.05
Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro. J Med Virol (2001) 1.04
A novel strand-specific RT-PCR for detection of hepatitis C virus negative-strand RNA (replicative intermediate): evidence of absence or very low level of HCV replication in peripheral blood mononuclear cells. J Virol Methods (2002) 1.02
Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood. J Virol (2001) 0.97
Divergent evolution of hepatitis C virus in liver and peripheral blood mononuclear cells of infected patients. J Med Virol (1999) 0.87
Longitudinal evaluation of the structure of replicating and circulating hepatitis C virus quasispecies in nonprogressive chronic hepatitis C patients. J Virol (2001) 0.83
International network of cancer genome projects. Nature (2010) 20.35
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology (2003) 2.71
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell (2013) 2.28
Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology (2011) 2.25
Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut (2010) 2.25
Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg (2012) 2.18
Pulmonary complications after elective liver transplantation-incidence, risk factors, and outcome. Transplantation (2012) 2.11
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg (2003) 2.02
Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol (2011) 1.99
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol (2006) 1.72
Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. J Hepatol (2010) 1.60
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl (2006) 1.53
Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation (2004) 1.51
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol (2010) 1.49
Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology (2008) 1.49
Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology (2008) 1.47
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. J Hepatol (2011) 1.46
HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology (2003) 1.44
The anhepatic phase of liver transplantation as a model for measuring the extra-hepatic replication of hepatitis C virus. J Hepatol (2005) 1.43
The histologic pattern of "biliary tract pathology" is accurate for the diagnosis of biliary complications. Am J Surg Pathol (2005) 1.42
Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin Transplant (2005) 1.41
Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology (2004) 1.41
Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol (2004) 1.41
Patients with acute liver failure listed for superurgent liver transplantation in France: reevaluation of the Clichy-Villejuif criteria. Liver Transpl (2015) 1.38
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One (2009) 1.33
Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl (2007) 1.31
Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl (2008) 1.30
Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology (2008) 1.30
Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int (2012) 1.30
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int (2011) 1.30
Evaluation of the one-step multiplex real-time reverse transcription-PCR ProFlu-1 assay for detection of influenza A and influenza B viruses and respiratory syncytial viruses in children. J Clin Microbiol (2007) 1.28
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl (2008) 1.27
Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology (2006) 1.22
The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology (2009) 1.21
The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos. Trans R Soc Trop Med Hyg (2010) 1.20
Plasma disappearance rate of indocyanine green: a tool to evaluate early graft outcome after liver transplantation. Liver Transpl (2009) 1.15
CTX-M beta-lactamase-producing Escherichia coli in long-term care facilities, France. Emerg Infect Dis (2004) 1.13
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? Transplantation (2015) 1.13
Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection. Hepatology (2007) 1.10
Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl (2005) 1.10
Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus. J Infect Dis (2002) 1.07
Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg (2002) 1.05
Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol (2006) 1.03
Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation (2003) 1.02
Therapeutic strategies in symptomatic portal biliopathy. Ann Surg (2007) 1.02
Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med (2013) 1.01
Probable intrafamily transmission of a highly virulent CTX-M-3-producing Escherichia coli belonging to the emerging phylogenetic subgroup D2 O102-ST405 clone. J Antimicrob Chemother (2010) 1.00
Diagnostic relevance of immunoglobulin G avidity for hepatitis A virus. J Clin Microbiol (2004) 1.00
Outbreak of Klebsiella pneumoniae producing KPC-2 and SHV-12 in a French hospital. J Antimicrob Chemother (2010) 1.00
Longitudinal prospective evaluation of quality of life in adult patients before and one year after liver transplantation. Liver Transpl (2003) 1.00
First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French university hospital. J Antimicrob Chemother (2005) 1.00
A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl (2008) 0.99
Management of HCV transplant patients with triple therapy. Liver Int (2014) 0.99
Male cell microchimerism in normal and diseased female livers from fetal life to adulthood. Hepatology (2005) 0.99
Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl (2005) 0.99
ATP release after partial hepatectomy regulates liver regeneration in the rat. J Hepatol (2009) 0.98
Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation. Am J Transplant (2003) 0.97
Epidemiology and genetic characterization of hepatitis A virus genotype IIA. J Clin Microbiol (2010) 0.94
Depressive symptoms predict long-term mortality after liver transplantation. J Psychosom Res (2011) 0.94
Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. J Infect Dis (2007) 0.93
Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl (2004) 0.93
Epidemiology of liver failure. Clin Res Hepatol Gastroenterol (2011) 0.93
The MTHFR 677C > T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis (2004) 0.92
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet (2007) 0.92
The difficulties of managing severe hepatitis B virus reactivation. Liver Int (2011) 0.91
Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transpl (2011) 0.91
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant (2009) 0.91
Cu-Zn super oxide dismutase as a potential antifibrotic drug for hepatitis C related fibrosis. Biomed Pharmacother (2005) 0.91